News Breaks |
|
|
| March 11, 2013 |
| 04:55 EDT |  | IRWD, IRWD, IRWD, LIFE, LIFE, LIFE, AZN, AZN, AZN, LLY, LLY, LLY, BMY, BMY, BMY, PFE, PFE, PFE, SNY, SNY, SNY, ABBV, ABBV, ABBV | EBD Group to host a conference
BIO-Europe 2013 is being held in Barcelona, Spain on March 11-13. |
|
|
News For IRWD;LIFE;AZN;LLY;BMY;PFE;SNY;ABBV From The Last 14 Days Check below for free stories on IRWD;LIFE;AZN;LLY;BMY;PFE;SNY;ABBV the last two weeks. |
|
|
| May 23, 2013 |
| 08:18 EDT |  | SNY | Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofi
 Subscribe for More Information |
|
| 08:14 EDT | | PFE | Carter's
Global Consumer Products Analysts discuss the possibility of China retiring the one-child policy within the year and potential implications for consumer products on an Analyst/Industry conference call. Relevant covered companies JNJ, PG, PFE, ABT, KMB, MJN and CRI which may be impacted and discussed on the Analyst/Industry conference call to be held on May 23 at 10 am. |
|
| 06:02 EDT |  | BMY | Bristol-Myers implied volatility at upper end of index mean range
|
|
| 05:47 EDT | | BMY | Stocks with implied volatility movement; SKS BMY
Stocks with implied volatility movement; Saks (SKS), Bristol-Myers (BMY) according to IVolatility. |
|
| May 22, 2013 |
| 16:00 EDT | | BMY | Options Update; May 22, 2013
Subscribe for More Information |
|
| 10:33 EDT | | BMY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
|
| 10:00 EDT |  | BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information |
|
| 08:59 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
| |
| 08:06 EDT | | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 06:47 EDT |  | IRWD | Ironwood likely to raise money again in early 2014, says Cantor
Cantor believes Ironwood's 10.5M share offering provides the company with adequate cash for another three-to-four quarters of operations. However, Cantor thinks Ironwood will need to raise money again in early 2014 and reiterates a Sell rating on the stock with a $9 price target. |
|
| 06:05 EDT | | BMY | Bristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 20:03 EDT |  | LIFE | Roche, Sigma-Aldrich teamed for Life bid, Reuters says
Subscribe for More Information |
|
| 18:30 EDT |  | IRWD | Ironwood 10.5M share Secondary priced at $13.00
JPMorgan, BofA/Merrill and Morgan Stanley acted as joint book running managers for the offering. |
|
| 10:00 EDT |  | LIFE | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Acquity Group (AQ) downgraded to Neutral from Buy at Roth Capital... Beazer Homes (BZH) downgraded to Neutral from Buy at Sterne Agee... CME Group (CME) downgraded to Neutral from Outperform at Macquarie... Carnival (CCL) downgraded to Neutral from Buy at UBS... Coach (COH) downgraded to Equal Weight from Overweight at Morgan Stanley... Deutsche Bank (DB) downgraded to Neutral from Overweight at JPMorgan... First Republic Bank (FRC) downgraded to Hold from Buy at Jefferies... Franklin Resources (BEN) downgraded to Neutral from Outperform at Macquarie... Life Technologies (LIFE) downgraded to Underperform from Outperform at CLSA... Oil States (OIS) downgraded to Neutral from Buy at Sterne Agee... Raymond James (RJF) downgraded to Market Perform from Outperform at Wells Fargo... VF Corp. (VFC) downgraded to Market Perform from Outperform at Wells Fargo... WellCare (WCG) downgraded to Neutral from Buy at Goldman... Huaneng Power (HNP) downgraded to Neutral from Buy at Citigroup... Comerica (CMA) downgraded to Neutral from Buy at DA Davidson... Beazer Homes (BZH) downgraded at Sterne Agee... Oil States (OIS) downgraded at Sterne Agee... eHealth (EHTH) downgraded to Neutral from Buy at Lazard Capital... Carnival (CCL) downgraded to Market Perform from Outperform at Wells Fargo... Warner Chilcott (WCRX) downgraded to Neutral from Positive at Susquehanna. |
|
| 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). |
|
| 07:44 EDT | | SNY | Sachs Associates to host a forum
Subscribe for More Information |
| |
|
|
|
|
